CASGEVY Revenue Surges 151% YoY to $76M; FDA Expands Approval to Children as Young as 2
CRSP is trading near its 52-week low of $44.12 (15% above the low).
Summary
CRISPR Therapeutics delivered a strong Q2 with CASGEVY revenue hitting $76 million, up 151% year-over-year and 78% sequentially, signaling rapid commercial uptake. The FDA's approval for children aged 2 and older opens a new patient segment of roughly 5,500, significantly expanding the addressable market. The company also advanced its pipeline with Phase 1 initiations for CTX340 in refractory hypertension and CTX460 in AATD, and a late-breaking abstract on CTX310 durability will be presented at ESC Congress on August 28. This follows the May 2026 news of six assets nearing pivotal data, reinforcing a broad catalyst-rich second half. With a cash runway extended to at least 24 months from the recent $600 million convertible note issuance, the financial position supports these advancing programs.
At the time of this announcement, CRSP was trading at $50.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.8B. The 52-week trading range was $44.12 to $78.48. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.